gout and glp 1 GLP-1 Drugs May Raise the Risk of Osteoporosis Gout, Study Suggests Glucagon-like peptide 1 receptor agonists:

A new study also suggests that patients taking semaglutide (Ozempic and Wegovy) may be at an increased risk of developing non-arteritic anterior ischemic optic neuropathy (NAION)

This underscores the importance of holistic weight management approaches, considering long-term health and behavioral factors

It runs roughly as follows

On April 1, 2026, the FDA approved orforglipron (Foundayo) by Eli Lilly for adults with obesity or overweight who also have weight-related medical problems to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity